NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.68
-0.33
-0.82%
After Hours: 40.62 +0.94 +2.37% 17:25 08/07 EDT
OPEN
39.90
PREV CLOSE
40.01
HIGH
41.03
LOW
39.24
VOLUME
648.68K
TURNOVER
--
52 WEEK HIGH
41.03
52 WEEK LOW
18.52
MARKET CAP
4.38B
P/E (TTM)
-779.5678
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NEO stock price target is 40.93 with a high estimate of 45.00 and a low estimate of 39.00.

EPS

NEO News

More
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
Motley Fool · 3d ago
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Neogenomics Inc (NEO) Q2 2020 Earnings Call Transcript
Joining me from our Fort Myers headquarters, with social distancing precautions in place, are Kathryn McKenzie, our Chief Financial Officer; Rob Shovlin, President of our Clinical Division; and Bill Bonello, President of our Informatics Division and Director o
Motley Fool · 07/28 17:30
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.Quarterly Results Earnings per share fell 157.14% over the past year to ($0.04), which beat the estimate of ($0.10).Revenue of $86,977,000 decreased by 14.49% from the same period
Benzinga · 07/28 14:34
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/28 13:55
NeoGenomics shares are trading lower despite reporting better-than-expected Q2 EPS and sales results.
Benzinga · 07/28 11:22
NeoGenomics Q2 EPS $(0.04) Beats $(0.10) Estimate, Sales $86.98M Beat $86.12M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.10) by 60 percent. This is a 157.14 percent decrease over earnings of $0.07 per share from the same
Benzinga · 07/28 11:19
NeoGenomics Q2 2020 Earnings Preview
Seeking Alpha · 07/27 18:10

Industry

Healthcare Facilities & Services
-0.13%
Healthcare Providers & Services
+0.87%

Hot Stocks

Symbol
Price
%Change

About NEO

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
More

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.